Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 26
- −5 vs. Q1 2025
- Portfolio value
- $153.8M
- −$30.2M (−16.4%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IONSIonis Pharmaceuticals Inc | COM | 500,000 | $19.8M | 12.8% | +250,000+100.0% | Added | History |
| RZLTRezolute, Inc. | COM NEW | 3,033,462 | $13.5M | 8.8% | +2,200,420+264.1% | Added | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 2,000,000 | $12.8M | 8.3% | +188,004+10.4% | Added | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 350,000 | $12.4M | 8.1% | +211,760+153.2% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,291,617 | $9.88M | 6.4% | −346,494−21.2% | Reduced | History |
| NGNENeurogene Inc. | COM | 485,859 | $7.26M | 4.7% | +14,895+3.2% | Added | History |
| AKBAAkebia Therapeutics, Inc. | COM | 1,985,915 | $7.23M | 4.7% | −2,987,925−60.1% | Reduced | History |
| EOLSEvolus, Inc. | COM | 720,118 | $6.63M | 4.3% | −224,625−23.8% | Reduced | History |
| ACLXArcellx, Inc. | COMMON STOCK | 100,000 | $6.58M | 4.3% | +55,000+122.2% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 200,000 | $6.26M | 4.1% | −45,272−18.5% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 103,848 | $5.54M | 3.6% | +103,848 | New | History |
| JBIOJade Biosciences, Inc. | COM NEW | 498,054 | $4.98M | 3.2% | +498,054 | New | History |
| CYTKCytokinetics Inc | COM NEW | 150,000 | $4.96M | 3.2% | −220,000−59.5% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 262,176 | $4.19M | 2.7% | −112,824−30.1% | Reduced | History |
| UNCYUnicycive Therapeutics, Inc. | COM NEW | 796,558 | $3.80M | 2.5% | −301,442−27.5% | ReducedConverted for a 1-for-10 split | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 323,170 | $3.65M | 2.4% | −691,197−68.1% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,500,000 | $3.46M | 2.3% | +1,500,000 | New | History |
| DBVTDBV Technologies S.A. | SPONSORED ADS | 374,679 | $3.43M | 2.2% | +374,679 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,170,194 | $3.33M | 2.2% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 300,000 | $3.29M | 2.1% | 00.0% | Unchanged | History |
| CNTXContext Therapeutics Inc. | COM | 4,683,711 | $3.07M | 2.0% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 225,000 | $2.96M | 1.9% | +75,298+50.3% | Added | History |
| SRRKScholar Rock Holding Corp | COM | 61,607 | $2.18M | 1.4% | +61,607 | New | History |
| PMNProMIS Neurosciences Inc. | COM | 2,645,128 | $1.28M | 0.8% | 00.0% | Unchanged | History |
| PLRXPliant Therapeutics, Inc. | COM | 850,000 | $986.0K | 0.6% | 00.0% | Unchanged | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 29,381 | $312.0K | 0.2% | −344,452−92.1% | Reduced | History |
Sold out since Q1 2025 (10)
Positions held at the end of Q1 2025 that are gone from this filing.
| Security | Class | Shares in Q1 2025 | Value in Q1 2025 | % of portfolio in Q1 2025 | History |
|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | COM | 750,000 | $10.1M | 5.5% | History |
| MRUSMerus N.V. | COM | 237,156 | $9.98M | 5.4% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 50,000 | $7.79M | 4.2% | History |
| DVAXDynavax Technologies Corp | COM NEW | 595,879 | $7.73M | 4.2% | History |
| DNTHDianthus Therapeutics, Inc. | COM | 275,000 | $4.99M | 2.7% | History |
| PCVXVaxcyte, Inc. | COM | 115,517 | $4.36M | 2.4% | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 2,728,910 | $4.23M | 2.3% | History |
| BEAMBeam Therapeutics Inc. | COM | 175,562 | $3.43M | 1.9% | History |
| MREOMereo BioPharma Group plc | SPON ADS | 1,275,000 | $2.87M | 1.6% | History |
| VYGRVoyager Therapeutics, Inc. | COM | 626,275 | $2.12M | 1.2% | History |